| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2000PNAS...97.8015Z |
| P356 | DOI | 10.1073/PNAS.120055097 |
| P932 | PMC publication ID | 16662 |
| P698 | PubMed publication ID | 10859350 |
| P5875 | ResearchGate publication ID | 12460017 |
| P2093 | author name string | K Sharma | |
| S Chen | |||
| D C Han | |||
| F N Ziyadeh | |||
| S W Hong | |||
| B B Hoffman | |||
| M Isono | |||
| M C Iglesias-De La Cruz | |||
| T A McGowan | |||
| P2860 | cites work | Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death | Q24563654 |
| Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells | Q28144178 | ||
| Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells | Q28283663 | ||
| Molecular mechanisms of diabetic renal hypertrophy | Q33702711 | ||
| Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta | Q34124569 | ||
| Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset | Q34193127 | ||
| Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy | Q34218935 | ||
| Advanced protein glycosylation in diabetes and aging | Q34298835 | ||
| Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice | Q34376178 | ||
| Structural-functional relationships in diabetic nephropathy | Q34616152 | ||
| Studies in the diabetic mutant mouse. VI. Evolution of glomerular lesions and associated proteinuria | Q36078021 | ||
| Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy | Q36133581 | ||
| Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy | Q37531744 | ||
| Phosphorylation of cAMP responsive element binding protein after treatment of mesangial cells with high glucose plus TGF beta or PMA. | Q38353386 | ||
| Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. | Q40416313 | ||
| The extracellular matrix in diabetic nephropathy | Q40779247 | ||
| Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration | Q41003628 | ||
| Significance of tubulointerstitial changes in diabetic renal disease | Q41055564 | ||
| Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease | Q41078715 | ||
| Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule | Q41121722 | ||
| The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms | Q41323510 | ||
| PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line | Q41440846 | ||
| Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy | Q41468370 | ||
| The renal hemodynamic basis of diabetic nephropathy | Q41468377 | ||
| Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule | Q41482068 | ||
| Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium | Q41581730 | ||
| High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta | Q41606229 | ||
| Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha | Q42491418 | ||
| Effect of high glucose on type IV collagen production by cultured glomerular epithelial, endothelial, and mesangial cells | Q42813010 | ||
| Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease | Q43737259 | ||
| Reversal of lesions of diabetic nephropathy after pancreas transplantation | Q47879758 | ||
| Pathophysiology of Progressive Nephropathies | Q57703963 | ||
| Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 | Q59066124 | ||
| A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy | Q60218055 | ||
| Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells | Q67997065 | ||
| Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium | Q68200998 | ||
| The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA | Q68884237 | ||
| Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats | Q70128476 | ||
| Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice | Q71006993 | ||
| Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease | Q71153700 | ||
| Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus | Q71219214 | ||
| Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy | Q71444175 | ||
| Expression of transforming growth factor-beta isoforms in human glomerular diseases | Q71568697 | ||
| Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40 | Q72093299 | ||
| mRNA expression of growth factors in glomeruli from diabetic rats | Q72210329 | ||
| Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse | Q72383093 | ||
| An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct | Q72411299 | ||
| Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy | Q72822585 | ||
| Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes | Q73117355 | ||
| Increased renal production of transforming growth factor-beta1 in patients with type II diabetes | Q73303097 | ||
| Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system | Q74326554 | ||
| The renal TGF-beta system in the db/db mouse model of diabetic nephropathy | Q74695280 | ||
| Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells | Q77324951 | ||
| High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta | Q78223135 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| prevention | Q1717246 | ||
| P304 | page(s) | 8015-8020 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice | |
| P478 | volume | 97 |
| Q34672674 | -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. |
| Q92535726 | A Significant Association Between Rhein and Diabetic Nephropathy in Animals: A Systematic Review and Meta-Analysis |
| Q36979205 | A glimpse of various pathogenetic mechanisms of diabetic nephropathy |
| Q35915947 | A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells |
| Q39793286 | A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis |
| Q96172032 | A negative feedback loop between JNK-associated leucine zipper protein and TGF-β1 regulates kidney fibrosis |
| Q28484321 | A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat |
| Q51598828 | A recombinant TGF-β1 vaccine ameliorates diabetic nephropathy in OLETF rats. |
| Q46860874 | A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. |
| Q82996792 | A sweet link between TGFbeta and vascular disease? |
| Q35622481 | AMP-activated protein kinase (AMPK) activation inhibits nuclear translocation of Smad4 in mesangial cells and diabetic kidneys |
| Q37259208 | AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function |
| Q58612380 | Aberrant DNA methylation of Tgfb1 in diabetic kidney mesangial cells |
| Q42373563 | Aberrant angiogenesis: The gateway to diabetic complications |
| Q36179961 | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model. |
| Q35931845 | Activation of AMP-activated protein kinase prevents TGF-β1-induced epithelial-mesenchymal transition and myofibroblast activation |
| Q35011158 | Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy |
| Q24324384 | Adiponectin regulates albuminuria and podocyte function in mice |
| Q50985567 | Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy? |
| Q37780646 | Advanced glycation end products, oxidative stress and diabetic nephropathy |
| Q52609089 | Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes. |
| Q36099419 | Agents in development for the treatment of diabetic nephropathy |
| Q59799713 | Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression |
| Q36109288 | Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice |
| Q35570438 | Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. |
| Q54593746 | Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. |
| Q47235747 | Amelioration of diabetic nephropathy by oral administration of d-α-tocopherol and its mechanisms. |
| Q40560353 | An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy. |
| Q34825044 | Angiotensin II and progressive renal insufficiency |
| Q35087034 | Angiotensin II and the glomerulus: focus on diabetic kidney disease |
| Q40269064 | Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy |
| Q41704433 | Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice |
| Q36019916 | Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria |
| Q39372162 | Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. |
| Q37887401 | Antifibrotic treatment and other new strategies for improving renal outcomes |
| Q44107276 | Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats |
| Q90149178 | Antioxidant Effects and Mechanisms of Medicinal Plants and Their Bioactive Compounds for the Prevention and Treatment of Type 2 Diabetes: An Updated Review |
| Q35876457 | Antiproteinuric effect of RAS blockade: new mechanisms |
| Q37306427 | Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis |
| Q35087535 | Appropriate drug therapy for improving outcomes in diabetic nephropathy |
| Q38422439 | Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis |
| Q44686981 | Attenuating effect of Fufang Xueshuantong Capsule on kidney function in diabetic nephropathy model |
| Q92438095 | Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1 |
| Q85268375 | Atypical transforming growth factor-β signaling in the hypothalamus is linked to diabetes |
| Q26744223 | Autophagy in kidney disease and aging: lessons from rodent models |
| Q35630822 | BAMBI elimination enhances alternative TGF-β signaling and glomerular dysfunction in diabetic mice |
| Q35924542 | BIM deficiency differentially impacts the function of kidney endothelial and epithelial cells through modulation of their local microenvironment |
| Q40658343 | BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells |
| Q57702774 | Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started |
| Q35071275 | Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy |
| Q39608719 | Blocking core fucosylation of TGF-β1 receptors downregulates their functions and attenuates the epithelial-mesenchymal transition of renal tubular cells |
| Q39509248 | C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes |
| Q42184591 | CCN3: a novel anti-fibrotic treatment in end-stage renal disease? |
| Q52589075 | CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. |
| Q33643812 | Candesartan Differentially Regulates Epithelial Sodium Channel in Cortex Versus Medulla of Streptozotocin-Induced Diabetic Rats |
| Q39641679 | Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy |
| Q38010045 | Cellular and molecular mechanisms of diabetic glomerulopathy |
| Q35306426 | Chlorogenic acid improves late diabetes through adiponectin receptor signaling pathways in db/db mice |
| Q41330819 | Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats |
| Q82929879 | Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model |
| Q37392107 | Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? |
| Q27333630 | Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism |
| Q41854992 | Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. |
| Q34810813 | Current concepts in radiation enteritis and implications for future clinical trials |
| Q36095577 | Decorin deficiency enhances progressive nephropathy in diabetic mice. |
| Q36020284 | Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice. |
| Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
| Q34195384 | Diabetic kidney disease in thedb/dbmouse |
| Q26996008 | Diabetic nephropathy and extracellular matrix |
| Q38227252 | Diabetic nephropathy--emerging epigenetic mechanisms |
| Q42230531 | Diacylglycerol Kinase alpha is Involved in the Vitamin E-Induced Amelioration of Diabetic Nephropathy in Mice. |
| Q53687857 | Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial-mesenchymal transition. |
| Q28580099 | Differential expression of type IV collagen isoforms in rat glomerular endothelial and mesangial cells |
| Q39801458 | Differential regulation of E-cadherin and alpha-smooth muscle actin by BMP 7 in human renal proximal tubule epithelial cells and its implication in renal fibrosis. |
| Q37733555 | Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis |
| Q30533827 | Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature |
| Q30398783 | Discovery of genes related to diabetic nephropathy in various animal models by current techniques |
| Q43218267 | Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. |
| Q91650519 | Diverse Role of TGF-β in Kidney Disease |
| Q35924552 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice |
| Q36536931 | Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage |
| Q40974328 | Dynamin-Related Protein 1 Deficiency Improves Mitochondrial Fitness and Protects against Progression of Diabetic Nephropathy |
| Q41091738 | ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. |
| Q59809200 | Early Enhanced Leucine-Rich -2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice |
| Q45016977 | Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. |
| Q34403105 | Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats |
| Q37298463 | Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice |
| Q43207567 | Effects of genistein on secretion of extracellular matrix components and transforming growth factor beta in high-glucose-cultured rat mesangial cells |
| Q51326179 | Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-β1/Smad2 pathway. |
| Q34682233 | Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy |
| Q36111664 | Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis. |
| Q46969176 | Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy |
| Q28579049 | Epigenetic Histone Methylation Modulates Fibrotic Gene Expression |
| Q34606895 | Epithelial cells as active player in fibrosis: findings from an in vitro model |
| Q37292388 | Essential role of TGF-beta signaling in glucose-induced cell hypertrophy |
| Q35083922 | Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice |
| Q39681036 | Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy. |
| Q51575431 | Evaluation of coverage variation of SNP chips for genome-wide association studies. |
| Q34784085 | Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy |
| Q37959165 | Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward |
| Q82568563 | Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy |
| Q37311890 | FOG2 protein down-regulation by transforming growth factor-β1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy. |
| Q24644869 | Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers |
| Q53225434 | Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice. |
| Q34408514 | Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathways |
| Q36533785 | Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice |
| Q53536824 | Fructose, but not dextrose, accelerates the progression of chronic kidney disease. |
| Q40139541 | Future strategies to prevent renal microvascular disease complications in diabetes. |
| Q41933558 | Gender Differences in the Acute Kidney Injury to Chronic Kidney Disease Transition. |
| Q51753611 | Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. |
| Q33656631 | Gene expression programs of mouse endothelial cells in kidney development and disease |
| Q37181917 | Genetic deficiency of anti-aging gene klotho exacerbates early nephropathy in STZ-induced diabetes in male mice |
| Q37260211 | Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury |
| Q24630117 | Getting 'Smad' about obesity and diabetes |
| Q33716952 | Ginger extract diminishes chronic fructose consumption-induced kidney injury through suppression of renal overexpression of proinflammatory cytokines in rats |
| Q34427292 | Global renal gene expression profiling analysis in B2-kinin receptor null mice: impact of diabetes |
| Q46790834 | Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli |
| Q34719321 | Glomerular filtration rate determinations in conscious type II diabetic mice |
| Q39604870 | Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes |
| Q35581294 | Growth factors and the development of diabetic nephropathy |
| Q26998726 | Heme oxygenase-1 as a target for TGF-β in kidney disease |
| Q35794379 | Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action |
| Q35791678 | Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction |
| Q84785418 | Hepatocyte growth factor suppresses transforming growth factor-beta-1 and type III collagen in human primary renal fibroblasts |
| Q36599920 | Heterozygous knockout of transforming growth factor-β1 protects Dahl S rats against high salt-induced renal injury |
| Q46348798 | High glucose activates PKC-zeta and NADPH oxidase through autocrine TGF-beta1 signaling in mesangial cells |
| Q36317393 | Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults |
| Q26773633 | Histological changes of kidney in diabetic nephropathy |
| Q28569252 | Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury |
| Q33399420 | Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease |
| Q26768865 | Hypoxia: The Force that Drives Chronic Kidney Disease |
| Q44522383 | IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose |
| Q89578732 | IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target |
| Q35994005 | Implementing large-scale ENU mutagenesis screens in North America |
| Q82126373 | Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy |
| Q35842105 | Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse |
| Q44540501 | Increased renal ENaC subunit and sodium transporter abundances in streptozotocin-induced type 1 diabetes |
| Q36906413 | Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice |
| Q34319638 | Inflammation in the pathogenesis of microvascular complications in diabetes |
| Q37319338 | Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats |
| Q45096217 | Inhibiting post-translational core fucosylation protects against albumin-induced proximal tubular epithelial cell injury |
| Q40456120 | Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. |
| Q53151512 | Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. |
| Q24671742 | Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA |
| Q26852400 | Inhibitors/antagonists of TGF-β system in kidney fibrosis |
| Q44599812 | Intercellular Adhesion Molecule-1–Deficient Mice Are Resistant Against Renal Injury After Induction of Diabetes |
| Q35563871 | Intervention strategies to prevent pathogenetic effects of glycated albumin |
| Q47890276 | Investigation of the Role of a Supplementation with Taurine on the Effects of Hypoglycemic-Hypotensive Therapy Against Diabetes-Induced Nephrotoxicity in Rats |
| Q39367421 | Involvement of Histone Lysine Methylation in p21 Gene Expression in Rat Kidney In Vivo and Rat Mesangial Cells In Vitro under Diabetic Conditions. |
| Q28574951 | Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells |
| Q45875016 | Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice |
| Q41276445 | Lack of type VIII collagen in mice ameliorates diabetic nephropathy |
| Q45178910 | Levels of transforming growth factor beta 1 in south Indian type 2 diabetic subjects |
| Q41827523 | Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. |
| Q33589120 | Major role for ACE-independent intrarenal ANG II formation in type II diabetes |
| Q46046763 | Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation |
| Q35649310 | Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease |
| Q36345943 | Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes |
| Q33633674 | Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease |
| Q46533470 | Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis |
| Q30429535 | Mesangial pathology in glomerular disease: targets for therapeutic intervention |
| Q44454818 | Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy |
| Q36124250 | MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. |
| Q40848218 | MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy |
| Q35907222 | MicroRNAs and the glomerulus |
| Q37258870 | MicroRNAs and their role in progressive kidney diseases |
| Q36166755 | MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets |
| Q37162322 | Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. |
| Q34557348 | Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy |
| Q37785319 | Molecular mechanisms in renal degenerative disease |
| Q26825286 | Molecular mechanisms of renal blood flow autoregulation |
| Q54376552 | Molecular mechanisms underlying the Nephroprotective effects of PACAP in diabetes. |
| Q38062404 | Molecular targets for treatment of kidney fibrosis |
| Q46381254 | Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril |
| Q92942740 | Nano-sized carriers in gene therapy for renal fibrosis in vivo |
| Q53160636 | Naringenin ameliorates streptozotocin-induced diabetic rat renal impairment by downregulation of TGF-β1 and IL-1 via modulation of oxidative stress correlates with decreased apoptotic events. |
| Q50086407 | Nephrotoxicity Induced by Cisplatin Intake in Experimental Rats and Therapeutic Approach of Using Mesenchymal Stem Cells and Spironolactone |
| Q26996084 | New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy |
| Q37598306 | New insights into molecular mechanisms of diabetic kidney disease |
| Q35988000 | New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology |
| Q37964276 | New options and perspectives for proteinuria management after kidney transplantation. |
| Q37741787 | New pharmacological treatments for improving renal outcomes in diabetes |
| Q36114984 | Nicotine exposure and the progression of chronic kidney disease: role of the α7-nicotinic acetylcholine receptor |
| Q34360219 | Nicotine signaling and progression of chronic kidney disease in smokers |
| Q46720418 | Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway |
| Q36402331 | Nondiabetic consequences of obesity on kidney |
| Q38198872 | Novel targets of antifibrotic and anti-inflammatory treatment in CKD. |
| Q38363997 | Novel therapies for FSGS: preclinical and clinical studies. |
| Q47357553 | Nrf2 Deficiency Upregulates Intrarenal Angiotensin-converting Enzyme-2 and Angiotensin 1-7 Receptor Expression and Attenuates Hypertension and Nephropathy in Diabetic Mice. |
| Q38282228 | Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis |
| Q34206321 | Obesity- and aging-induced excess of central transforming growth factor-β potentiates diabetic development via an RNA stress response |
| Q28484212 | Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease |
| Q84742870 | Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition |
| Q35168051 | Outcome studies in diabetic nephropathy |
| Q37635850 | Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-β1 signaling in interstitial lung disease |
| Q36923658 | Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice |
| Q43269412 | Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-beta activity and TGF-beta1 expression. |
| Q26741451 | Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease |
| Q44393197 | P38 mitogen-activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells |
| Q38053074 | Pathophysiology of the aging kidney and therapeutic interventions |
| Q38111707 | Pathophysiology of the diabetic kidney. |
| Q28070053 | Pericytes, an overlooked player in vascular pathobiology |
| Q33701827 | Periostin-Binding DNA Aptamer Treatment Ameliorates Peritoneal Dialysis-Induced Peritoneal Fibrosis |
| Q92844811 | Petchiether A attenuates obstructive nephropathy by suppressing TGF-β/Smad3 and NF-κB signalling |
| Q46681465 | Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model |
| Q36753326 | Phenotypic transitions and fibrosis in diabetic nephropathy |
| Q35012444 | Pirfenidone for diabetic nephropathy |
| Q37297659 | Pirfenidone is renoprotective in diabetic kidney disease |
| Q33960082 | Plasminogen activator inhibitor-1 and the kidney |
| Q37340690 | Podocytes: the Weakest Link in Diabetic Kidney Disease? |
| Q38186986 | Potential approaches to reverse or repair renal fibrosis |
| Q34481843 | Potential methods to prevent interstitial fibrosis in renal disease |
| Q39126178 | Potential regulatory mechanisms of lncRNA in diabetes and its complications |
| Q38217204 | Potential role of Akt signaling in chronic kidney disease |
| Q57925077 | Pre-pubertal induction of experimental diabetes protects against early renal macrophage infiltration |
| Q36015077 | Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies |
| Q37290939 | Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection |
| Q44628691 | Prevention of Hypertension Attenuates Albuminuria and Renal Expression of Fibronectin in Diabetic Spontaneously Hypertensive Rats |
| Q74586449 | Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase |
| Q47768797 | Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition |
| Q40549158 | Proteases in Plasma and Kidney of db/db Mice as Markers of Diabetes-Induced Nephropathy |
| Q35876750 | Protective effect of TRPV1 against renal fibrosis via inhibition of TGF-β/Smad signaling in DOCA-salt hypertension |
| Q33722952 | Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes. |
| Q42263637 | RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy |
| Q38192852 | Reactive oxygen species in diabetic nephropathy: friend or foe? |
| Q34603387 | Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells |
| Q34682220 | Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy |
| Q37819453 | Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy |
| Q47828965 | Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion. |
| Q28360679 | Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent |
| Q46492805 | Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling |
| Q28205154 | Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms |
| Q34211573 | Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids |
| Q36785571 | Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment |
| Q43099042 | Regulation of transforming growth factor-beta1 by insulin in prediabetic African Americans |
| Q37780781 | Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy |
| Q44127136 | Relationship between transforming growth factor beta1 and progression of hypertensive renal disease |
| Q38148750 | Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria |
| Q35167826 | Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. |
| Q46473326 | Renal activity of Akt kinase in obese Zucker rats |
| Q36016743 | Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells. |
| Q37253944 | Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney |
| Q51805875 | Renal injury: similarities and differences in male and female rats with the metabolic syndrome. |
| Q36517099 | Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats |
| Q51303502 | Reno-protection of G004, a novel anti-diabetic sulfonylurea in db/db mice. |
| Q36115290 | Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats |
| Q44499796 | Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy |
| Q54394118 | Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. |
| Q38217707 | Research progress in signalling pathway in diabetic nephropathy |
| Q30830157 | Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy |
| Q36265641 | Reversal of diabetic retinopathy in streptozotocin induced diabetic rats using traditional Indian anti-diabetic plant,Azadirachta indica (L.). |
| Q44247933 | Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. |
| Q54640476 | Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. |
| Q28073885 | Rodent models of diabetic nephropathy: their utility and limitations |
| Q38120646 | Role of dyslipidemia in patients with chronic kidney disease |
| Q37762920 | Role of transforming growth factor-β in airway remodeling in asthma |
| Q41642566 | Rutin ameliorates renal fibrosis and proteinuria in 5/6-nephrectomized rats by anti-oxidation and inhibiting activation of TGFβ1-smad signaling. |
| Q44535802 | SDF-1α reduces fibronectin expression in rat mesangial cells induced by TGF-β1 and high glucose through PI3K/Akt pathway |
| Q46797106 | SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice |
| Q34747455 | Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis |
| Q43633024 | Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes. |
| Q26768469 | Serum TGF-β1 as a Biomarker for Type 2 Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials |
| Q34576663 | Serum- and glucocorticoid-dependent kinase, cell volume, and the regulation of epithelial transport. |
| Q35791976 | Signaling mechanisms in the regulation of renal matrix metabolism in diabetes |
| Q35098290 | Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus |
| Q38363395 | Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells |
| Q38072702 | Smoking in diabetic nephropathy: sparks in the fuel tank? |
| Q45159120 | Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice |
| Q50661031 | Soluble betaglycan reduces renal damage progression in db/db mice. |
| Q41358378 | Stem cell transplantation increases antioxidant effects in diabetic mice. |
| Q28078020 | Stop chronic kidney disease progression: Time is approaching |
| Q36234919 | Sugar, sex, and TGF-β in diabetic nephropathy |
| Q42450892 | Suppressions of chronic glomerular injuries and TGF-β1production by HGF in attenuation of murine diabetic nephropathy |
| Q36026798 | Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions |
| Q40812992 | TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. |
| Q44129279 | TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells |
| Q45220024 | TGF-beta impairs renal autoregulation via generation of ROS. |
| Q28367170 | TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy |
| Q36775661 | TGF-β signaling in the kidney: profibrotic and protective effects |
| Q50483893 | TGF-β1 monoclonal antibody: Assessment of embryo-fetal toxicity in rats and rabbits. |
| Q42837787 | TGFβ-induced PI 3 kinase-dependent Mnk-1 activation is necessary for Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy |
| Q28975741 | TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion |
| Q34392664 | Targeted Disruption of Guanylyl Cyclase-A/Natriuretic Peptide Receptor-A Gene Provokes Renal Fibrosis and Remodeling in Null Mutant Mice: Role of Proinflammatory Cytokines |
| Q30472688 | Targeted renal therapies through microbubbles and ultrasound☆ |
| Q73007323 | Targeting TGF could counter diabetic nephropathy |
| Q58700082 | Targeting TGF-β Signaling in Kidney Fibrosis |
| Q37399929 | Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice |
| Q87814876 | Taxus chinensis ameliorates diabetic nephropathy through down-regulating TGF-β1/Smad pathway |
| Q39653852 | Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: Involvement of SIRT1 and TGF-β1 pathway |
| Q36918392 | The Extract of Litsea japonica Reduced the Development of Diabetic Nephropathy via the Inhibition of Advanced Glycation End Products Accumulation in db/db Mice |
| Q42505245 | The Increased Transforming Growth Factor-β Signaling Induced by Diabetes Protects Retinal Vessels |
| Q54688757 | The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes. |
| Q37590421 | The genetics of diabetic nephropathy. |
| Q34333423 | The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy |
| Q97549197 | The mechanisms of ameliorating effect of a green tea polyphenol on diabetic nephropathy based on diacylglycerol kinase α |
| Q35630847 | The missing link: studying the alternative TGF-β pathway provides a unifying theory for different components of diabetic nephropathy |
| Q35689005 | The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis |
| Q38172403 | The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis |
| Q43017133 | The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. |
| Q34527184 | The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential |
| Q34979592 | The proximal tubule in the pathophysiology of the diabetic kidney |
| Q35168076 | The relationship of cigarette smoking to end-stage renal disease |
| Q38087656 | The renal endothelium in diabetic nephropathy |
| Q34472190 | The role of Krüppel-like factor 4 in transforming growth factor-β-induced inflammatory and fibrotic responses in human proximal tubule cells |
| Q57801450 | The role of klotho in chronic kidney disease |
| Q30340930 | The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. |
| Q39474702 | The roles of connective tissue growth factor and integrin-linked kinase in high glucose-induced phenotypic alterations of podocytes |
| Q33966594 | The thrombospondin 1-TGF-beta axis in fibrotic renal disease |
| Q47417902 | The time has come to target connective tissue growth factor in diabetic complications |
| Q37236249 | The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy |
| Q90171437 | The tubular hypothesis of nephron filtration and diabetic kidney disease |
| Q46812245 | Theobromine increases NAD⁺/Sirt-1 activity and protects the kidney under diabetic conditions |
| Q30423005 | Therapeutic Modalities in Diabetic Nephropathy: Future Approaches |
| Q35079607 | Therapeutic targets for treating fibrotic kidney diseases |
| Q37464743 | Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials |
| Q47243282 | Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease |
| Q91714322 | Transforming Growth Factor-Beta1 in Diabetic Kidney Disease |
| Q37428739 | Transforming growth factor beta as a therapeutic target in systemic sclerosis |
| Q36102963 | Transforming growth factor beta contributes to progressive diabetic nephropathy |
| Q83104000 | Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells |
| Q34389106 | Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease |
| Q44298458 | Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling |
| Q28292776 | Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy |
| Q36810701 | Transforming growth factor-β1 and diabetic nephropathy |
| Q47585220 | Transforming growth factor-β1 and phosphatases modulate COX-2 protein expression and TAU phosphorylation in cultured immortalized podocytes |
| Q33995115 | Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis |
| Q48444056 | Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice |
| Q36297539 | Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy |
| Q42704546 | Type VIII collagen modulates TGF-β1-induced proliferation of mesangial cells |
| Q47757479 | Tyrosines-740/751 of PDGFRβ contribute to the activation of Akt/Hif1α/TGFβ nexus to drive high glucose-induced glomerular mesangial cell hypertrophy |
| Q79199313 | Ultrastructural basement membrane topography of the bladder epithelium |
| Q84323641 | Uninephrectomy of diabetic OVE26 mice greatly accelerates albuminuria, fibrosis, inflammatory cell infiltration and changes in gene expression |
| Q40593056 | Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucose-response element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway |
| Q35393446 | Uric acid as a mediator of diabetic nephropathy |
| Q55084015 | Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy. |
| Q53914796 | Urinary transforming growth factor-beta(1), collagen IV and the effect of insulin in children at diagnosis of diabetes mellitus. |
| Q39847514 | Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta 1 and VEGF. |
| Q45147720 | Use of genetic mouse models in the study of diabetic nephropathy |
| Q35739805 | Use of genetic mouse models in the study of diabetic nephropathy |
| Q34003179 | VEGF regulates TRPC6 channels in podocytes |
| Q36537262 | Vascular complications of diabetes: mechanisms of injury and protective factors |
| Q37298460 | Vascular consequences of dietary salt intake |
| Q83180988 | Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor |
| Q40628313 | Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells |
| Q37980677 | What are new avenues for renal protection, in addition to RAAS inhibition? |
| Q36538396 | What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? |
| Q53624421 | [The epithelial-mesenchymal transition and fibrosis of the renal transplant]. |
| Q44414157 | c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones |
Search more.